Hinduja Global Solutions (HGS) Q2 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 24/25 earnings summary
2 Nov, 2026Executive summary
Q2 FY2025 operating revenue was ₹1,087.15 crore, down 7.9% YoY; EBITDA was ₹154.8 crore at a 12.8% margin.
H1 operating revenue was ₹2,179.1 crore, down 5.8% YoY; EBITDA was ₹298.3 crore at a 12.3% margin.
H1 PAT of ₹111.01 crore included a ₹218.54 crore gain on the healthcare-business sale; continuing operations recorded an H1 loss after tax of ₹107.53 crore.
Macro pressure, delayed contract awards and lower UK revenue weighed on results, while management cited healthy client expansion opportunities and pipeline.
Financial highlights
Q2 total income was ₹1,207.58 crore, down 6.2% YoY; operating revenue was ₹1,087.15 crore and EBITDA was ₹154.8 crore.
Q2 continuing-operations loss after tax was ₹50.51 crore.
H1 total income was ₹2,426.2 crore, down 4.3% YoY; EBITDA was ₹298.3 crore, down 24.7% YoY.
H1 PBT was a loss of ₹84.9 crore; reported PAT of ₹111.01 crore included discontinued operations.
Outlook and guidance
FY25 business and operational targets were on track; management expected faster decisions as election uncertainty cleared and described client engagement and pipeline as healthy.
Two North American core technology-services contracts are expected to generate revenue during FY25, with fuller benefits in FY26 and potential longer-term margin improvement.
Management’s 2027 ambition is to become a preferred digital transformation partner for major global brands, expanding digital operations and AI-supported services.
Technology-enabled CX pipeline includes digital-services interest from the UK, Australia and the US; South Africa prospects were also described as promising.
OneBusiness completed a pilot, with commercial rollout planned across key markets; traction was expected by Q4.
Latest events from Hinduja Global Solutions
- Q2 operating EBITDA rose 30% as cost discipline offset muted growth.HGS
Q2 23/24 - Q3 EBITDA surged and PBT turned positive amid digital growth and uncertain demand.HGS
Q3 23/24 - FY2024 operating EBITDA rose 45.8% as AI-led growth advanced amid unresolved tax-search exposure.HGS
Q4 23/24 - One-time costs pressured margins; healthcare-sale gain lifted PAT, with recovery expected from Q2.HGS
Q1 24/25 - FY25 PAT included a healthcare-sale gain as strategy pivots to AI-led digital growth.HGS
Q4 24/25 - Q3 EBITDA margin reached 19% as AI-led growth advanced amid near-term revenue pressure.HGS
Q3 24/25 - Margin expansion and digital traction amid softer Q1 revenue.HGS
Q1 25/26 - FY26 EBITDA fell 20.1%; record wins and Project GANGA support growth prospects.HGS
Q4 25/26 - Revenue held broadly steady as continuing losses widened; client wins and Project GANGA advanced.HGS
Q1 26/27